Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Myeloid Therapeutics
Avacta Life Sciences Ltd
Innate Pharma
M.D. Anderson Cancer Center
Nurix Therapeutics, Inc.
Exelixis
Jonsson Comprehensive Cancer Center
Xencor, Inc.
University of Virginia
NextPoint Therapeutics, Inc.
Monopar Therapeutics
Monopar Therapeutics
Orion Biotechnology Polska Sp. z o.o.
Daiichi Sankyo
Carisma Therapeutics Inc
Zumutor Biologics Inc.
Xencor, Inc.
Pliant Therapeutics, Inc.
Atreca, Inc.
Fate Therapeutics
Tempest Therapeutics
Fate Therapeutics
Xencor, Inc.
Herlev Hospital
Xencor, Inc.
Ludwig Institute for Cancer Research
Incyte Corporation
Incyte Corporation
Merrimack Pharmaceuticals
Corcept Therapeutics